Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion type Assertion NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_head.
- NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion description "[We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_provenance.
- NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion evidence source_evidence_literature NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_provenance.
- NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion SIO_000772 12890841 NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_provenance.
- NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion wasDerivedFrom befree-20140225 NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_provenance.
- NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_assertion wasGeneratedBy ECO_0000203 NP624210.RABuST5h-mBOsQ-m0_SRK0C_LzwbXcqhbI6AUmKZiVGG0130_provenance.